
    
      The subjects received the drug treatment for a total of 96 weeks, which was divided into two
      stages: the first stage: 0-24 weeks as the core treatment period and 25-48 weeks as the
      extended treatment period. The second stage: 49-96 weeks is the extended treatment
      periodï¼Œsubjects will enter the second stage of treatment according to the dose of the first
      stage. When the efficacy data of the first phase determine the optimal dose of QL-007, all
      subjects entering the second phase will receive the optimal dose of QL-007 and continue
      treatment with tenofovir dipirofurate fumarate (QL-007 XX mg+TDF) for the second phase 49-96
      weeks of extended treatment.
    
  